Document Detail


Cost-effectiveness of implantable cardioverter-defibrillators.
MedLine Citation:
PMID:  16207849     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Eight randomized trials have evaluated whether the prophylactic use of an implantable cardioverter-defibrillator (ICD) improves survival among patients who are at risk for sudden death due to left ventricular systolic dysfunction but who have not had a life-threatening ventricular arrhythmia. We assessed the cost-effectiveness of the ICD in the populations represented in these primary-prevention trials. METHODS: We developed a Markov model of the cost, quality of life, survival, and incremental cost-effectiveness of the prophylactic implantation of an ICD, as compared with control therapy, among patients with survival and mortality rates similar to those in each of the clinical trials. We modeled the efficacy of the ICD as a reduction in the relative risk of death on the basis of the hazard ratios reported in the individual clinical trials. RESULTS: Use of the ICD increased lifetime costs in every trial. Two trials--the Coronary Artery Bypass Graft (CABG) Patch Trial and the Defibrillator in Acute Myocardial Infarction Trial (DINAMIT)--found that the prophylactic implantation of an ICD did not reduce the risk of death and thus was both more expensive and less effective than control therapy. For the other six trials--the Multicenter Automatic Defibrillator Implantation Trial (MADIT) I, MADIT II, the Multicenter Unsustained Tachycardia Trial (MUSTT), the Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) trial, the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial, and the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)--the use of an ICD was projected to add between 1.01 and 2.99 quality-adjusted life-years (QALY) and between 68,300 dollars and 101,500 dollars in cost. Using base-case assumptions, we found that the cost-effectiveness of the ICD as compared with control therapy in these six populations ranged from 34,000 dollars to 70,200 dollars per QALY gained. Sensitivity analyses showed that this cost-effectiveness ratio would remain below 100,000 dollars per QALY as long as the ICD reduced mortality for seven or more years. CONCLUSIONS: Prophylactic implantation of an ICD has a cost-effectiveness ratio below 100,000 dollars per QALY gained in populations in which a significant device-related reduction in mortality has been demonstrated.
Authors:
Gillian D Sanders; Mark A Hlatky; Douglas K Owens
Related Documents :
480559 - Energy levels and patient weight in ventricular defibrillation.
18950299 - Icd implantation and arrhythmia-free survival in patients with depressed lv function fo...
15010739 - Detection of myocardial injury after internal cardioversion for atrial fibrillation.
25375999 - Effect of global cardiac ischemia on human ventricular fibrillation: insights from a mu...
18195289 - Fish-oil supplementation in patients with implantable cardioverter defibrillators: a me...
10423669 - Implantable cardioverter-defibrillator follow-up: what everyone needs to know.
23485059 - A sinister plot? facts, beliefs, and stereotypes about the left-handed personality.
20008329 - Cardiac sarcoma presenting as heart failure and diagnosed as recurrent myxoma by echoca...
22796089 - Transient st-segment elevation resembling acute myocardial infarction in a patient with...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  The New England journal of medicine     Volume:  353     ISSN:  1533-4406     ISO Abbreviation:  N. Engl. J. Med.     Publication Date:  2005 Oct 
Date Detail:
Created Date:  2005-10-06     Completed Date:  2005-10-11     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0255562     Medline TA:  N Engl J Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1471-80     Citation Subset:  AIM; IM    
Copyright Information:
Copyright 2005 Massachusetts Medical Society.
Affiliation:
Duke Clinical Research Institute, Duke University, Durham, NC 27715, USA. gillian.sanders@duke.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Cost-Benefit Analysis
Death, Sudden, Cardiac / epidemiology,  prevention & control*
Decision Support Techniques
Defibrillators, Implantable / economics*
Direct Service Costs*
Heart Diseases / economics,  therapy*
Humans
Markov Chains
Mortality
Quality of Life
Quality-Adjusted Life Years
Randomized Controlled Trials as Topic
Risk
Survival Analysis
Comments/Corrections
Comment In:
N Engl J Med. 2005 Oct 6;353(14):1513-5   [PMID:  16207856 ]
ACP J Club. 2006 Mar-Apr;144(2):52   [PMID:  16539367 ]
Evid Based Cardiovasc Med. 2006 Mar;10(1):56-8   [PMID:  16530689 ]
N Engl J Med. 2006 Jan 12;354(2):205-7; author reply 205-7   [PMID:  16411302 ]
N Engl J Med. 2006 Jan 12;354(2):205-7; author reply 205-7   [PMID:  16407520 ]
N Engl J Med. 2006 Jan 12;354(2):205-7; author reply 205-7   [PMID:  16411295 ]
Evid Based Cardiovasc Med. 2006 Mar;10(1):56-8   [PMID:  16530690 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Outbreak of Vibrio parahaemolyticus gastroenteritis associated with Alaskan oysters.
Next Document:  Role of GABAergic inhibition in shaping odor-evoked spatiotemporal patterns in the Drosophila antenn...